Johnson & Johnson JNJ
Set alert
At close
Pre-market · Nov 3, 7:55 AM ET
- YTD
- +30.74%
- 1 year
- +45.26%
- Open
- 272.06
- Prev close
- 273.20
- Mkt cap
- 651.32B
- Vol
- 8.26M
- Avg vol
- 6.89M
- EPS
- 6.59
- P/E
- 41.06
- Div yield
- 1.95%
More statistics
- Low
- 267.44
- High
- 273.01
- Forward P/E
- 23.29
- Beta
- 0.20
- Short ratio
- 2.23
- Inst. own
- 76.78%
- Dividend
- 5.36
- Ex-div date
- Nov 23, 2026
- Earnings
- Jan 26, 2027
- 50-d avg
- 265.60
- 200-d avg
- 246.99
- 1y target
- 279.41
5D chart
Signals (114)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 3:55 PM | 16 hours ago |
| RSI: Overbought | Nov 2, 3:30 PM | 16 hours ago |
| RSI: Overbought | Nov 2, 3:00 PM | 16 hours ago |
| RSI: Overbought | Nov 2, 2:45 PM | 17 hours ago |
| SMA: Bullish | Nov 2, 1:50 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 1:40 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 1:30 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 1:20 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 1:05 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 1:00 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 12:50 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 12:45 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 11:55 AM | 20 hours ago |
| SMA: Bullish | Nov 2, 11:35 AM | 20 hours ago |
| SMA: Bearish | Nov 2, 11:10 AM | 20 hours ago |
| SMA: Bullish | Nov 2, 11:05 AM | 20 hours ago |
| SMA: Bearish | Nov 2, 10:55 AM | 21 hours ago |
| SMA: Bullish | Nov 2, 10:35 AM | 21 hours ago |
Newest 20 of 114.
News
35 minutes ago benzinga.com
Jim Cramer Likes This Industrial Stock: ‘It’s Come Down A Great Deal’
Cramer recommends Howmet and J&J, prefers Micron over Western Digital, criticizes Nebius, and favors Lam Research over KLA.
19 hours ago fool.com
The Best Dividend Stocks to Buy With $5,000 in November
AbbVie survived its loss of Humira, and its profits are soaring. J&J's streamlining efforts are paying off.
20 hours ago benzinga.com
Growth And Cyclical Sectors Lead Monday Trading
Seven sectors are higher and four are lower in Monday’s regular session, with growth and cyclical sectors splitting the top of the table. The leaders are separated rather than clustered, with no…
23 hours ago 247wallst.com
2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever
Arthritis flares, cholesterol checks and cancer treatments arrive on their own schedule, in recessions and booms alike, which is why healthcare draws attention from retirees building an income plan.…
23 hours ago 247wallst.com
3 Best Dividend Stocks for a $100,000 Passive Income Strategy
Retirement flips the income question around. After decades of collecting a paycheck, retirees need assets that send cash on a predictable schedule, and that cash has to hold up when markets turn…
1 day ago defenseworld.net
33,097 Johnson & Johnson $JNJ Shares Bought by International Assets Investment Management LLC
International Assets Investment Management LLC raised its stake in Johnson and Johnson (NYSE: JNJ) by 195.8% in the third quarter, according to the company in its most recent filing with the…
1 day ago defenseworld.net
Gray Private Wealth LLC Acquires New Position in Johnson & Johnson $JNJ
Gray Private Wealth LLC bought a new position in Johnson and Johnson (NYSE: JNJ) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange…
1 day ago 247wallst.com
4 Blue-Chip Dividend Stocks That Kept Raising Payouts Through 2008 and 2020
Some dividend stocks cut payouts the moment a recession hits, but a small group of blue chips kept raising theirs through the 2008 financial crisis and the 2020 shutdowns.
1 day ago businesswire.com
Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
SAN DIEGO--(BUSINESS WIRE)-- #PressRelease--Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific…
2 days ago 247wallst.com
Suze Orman Says You Don’t Have to Buy Every Market Dip. Here’s Why
Suze Orman says sitting still during a market sell-off is a legitimate strategy, but retirees paying bills from a falling portfolio rarely get that luxury. A specific kind of stock changes that…
2 days ago 247wallst.com
Roth IRA vs. Taxable Account: How Much of $17,985 in Blue-Chip Dividends Would You Keep?
A $600,000 portfolio spread across four blue-chip dividend legends generates a surprisingly large tax bill every year, and the difference between where you hold these shares could quietly reshape…
3 days ago fool.com
Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.
Johnson & Johnson is a large medical device and pharmaceutical company. Third-quarter 2026 earnings fell nearly 96% year over year.
3 days ago 247wallst.com
No Tricks, Just Treats: 3 Dividend Stocks With Payouts You Can Trust
Some dividend yields look generous right up until the moment they get cut, but a handful of companies have funded unbroken payout streaks through recessions, patent cliffs, and commodity shocks.…
3 days ago zacks.com
JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4?
J&J's MedTech growth slows in Q3 amid international market challenges and Abiomed weakness.
3 days ago 247wallst.com
No Tricks, Just Treats: 3 Dividend Stocks With Payouts You Can Trust
On Halloween eve, the scariest thing an income investor can find is a yield that looks generous but is stressed. That is a payout the business can barely fund, and it tends to get cut at the worst…
3 days ago 247wallst.com
4 Dividend Kings With 50-Plus Years of Payout Increases for Retirement Income
Four companies have raised their dividends every single year for at least half a century, but not all of them carry the same risks heading into retirement.
4 days ago youtube.com
The Big 3: AAPL, JNJ, MMM
As a tech selloff sparked by Alphabet (GOOGL) earnings grips the stock market, Dan Deming continues to see the rotation as the biggest unsung headline for equities. As for today's Big 3, he expects…
4 days ago 247wallst.com
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher
Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook.
4 days ago zacks.com
Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm…
4 days ago 247wallst.com
VYM's Price May Be Soaring, but Its Dividend Isn't Keeping Up
VYM has handed shareholders a remarkable run, but the gap between share price growth and dividend growth is raising an uncomfortable question for retirees counting on that quarterly check.
4 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact…
4 days ago benzinga.com
Microsoft Goes Jumbo: $25 Billion Bond Sale in the Works
Microsoft plans at least $25B in bonds, its first debt sale since 2017, to fund capital needs as AI-driven spending surges.
5 days ago 247wallst.com
4 Dividend-Paying Dow Jones Industrial Stocks That Beat Q3 Estimates
Four blue-chip Dow dividend payers just topped Wall Street's third-quarter estimates, but their payout stories diverge sharply on yield, coverage, and growth. One just cut its quarterly check while…
5 days ago seekingalpha.com
Johnson & Johnson: Strong Q3 Growth, But 2027 Could Test Its Earnings
Johnson & Johnson reported Q3 revenue of $25.4 billion, supported by Innovative Medicine's 7.9% operational growth, while MedTech lagged at 2.5%. Management raised its 2026 guidance and adjusted EPS.…
5 days ago seekingalpha.com
Best Dividend Aristocrats For November 2026
Dividend Aristocrats underperformed SPY in September but rebounded sharply in October, narrowing the YTD gap. NOBL and the average Aristocrat have YTD returns of 13.13% and 13.35%, trailing SPY's…
5 days ago benzinga.com
Cyclicals Lead Sectors In Wednesday Trading As Real Estate Trails
Four sectors are higher and seven are lower in Wednesday’s regular session, with cyclical and defensive sectors split at the top of the table. The leaders are separated rather than clustered, with…
5 days ago 247wallst.com
Why JEPI’s Total Return Has Outpaced Its Payout
JEPI's share price keeps climbing while its monthly cash payments quietly shrink, and the reason behind that split reveals something most income investors never check before buying a covered-call…
6 days ago defenseworld.net
Johnson & Johnson $JNJ Stock: Bernardo Wealth Planning LLC Raises Holdings
Bernardo Wealth Planning LLC boosted its position in shares of Johnson and Johnson (NYSE: JNJ) by 105.8% during the undefined quarter, according to its most recent Form 13F filing with the Securities…
6 days ago defenseworld.net
29,241 Shares of Johnson & Johnson $JNJ Acquired by BG Investment Services LLC
BG Investment Services LLC acquired a new position in shares of Johnson and Johnson (NYSE: JNJ) during the third quarter, according to the company in its most recent Form 13F filing with the…
6 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to…
6 days ago 247wallst.com
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance…
6 days ago zacks.com
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
6 days ago 247wallst.com
$200,000 in Dividend Stocks: How Much More Could You Keep in a Roth IRA?
Parking six popular dividend stocks in a taxable account quietly hands the IRS a cut of every payout, and one holding in your portfolio is almost certainly the biggest culprit.
6 days ago 247wallst.com
CDs or Dividend Stocks: Which Pays Retirees Better Right Now?
Johnson and Johnson, Procter and Gamble, and Coca-Cola all beat the national CD average on yield, but the real comparison has nothing to do with today's rate and everything to do with what happens to…
-
1 week ago benzinga.com
Johnson & Johnson Plans To Hold Enterprise Business Review On Dec. 8
Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026. During the event, Company leaders will provide a detailed review of…
1 week ago businesswire.com
Johnson & Johnson to Host Enterprise Business Review
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026. During the event, Company…
1 week ago defenseworld.net
Fifth Third Wealth Advisors LLC Purchases 2,845 Shares of Johnson & Johnson $JNJ
Fifth Third Wealth Advisors LLC lifted its position in Johnson and Johnson (NYSE: JNJ) by 4.9% in the undefined quarter, according to the company in its most recent filing with the Securities and…
1 week ago defenseworld.net
Barrett & Company Inc. Acquires 50,741 Shares of Johnson & Johnson $JNJ
Barrett and Company Inc. boosted its stake in Johnson and Johnson (NYSE: JNJ) by 531.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission…
1 week ago benzinga.com
Nasdaq Gains Over 200 Points As Chip Stocks Rise: Investor Sentiment Improves, Fear & Greed Index Moves to ‘Fear’ Zone
U.S. stocks rose Monday as AI shares gained, but CNN’s Fear & Greed Index remained in the Fear zone at 27. Investors await major earnings.
1 week ago benzinga.com
Coca-Cola, Boeing and 3 Stocks to Watch Heading Into Tuesday
Stocks in focus: Coca-Cola and Boeing report earnings; Whirlpool cuts guidance after a miss, while Celestica beats estimates and raises outlook.
1 week ago benzinga.com
Mark Cuban Warns CEOs If Your Health Benefits Do Not Actually Help Employees You Are Legally Liable - 'It’s All On You’
Billionaire entrepreneur Mark Cuban says company leaders who treat employee health benefits as someone else's problem may be setting themselves up for a legal reckoning, and he wants them to know it.
1 week ago benzinga.com
Meta Tumbles 6% on AI Spending Fears, 10-Year Yield Falls Below 5%: Stock Market Today
Meta's higher AI spending plan drags tech lower as Treasurys rally and the 10-year yield drops below 5%. Gold, silver and Bitcoin fall; oil climbs.
1 week ago benzinga.com
Defensives Lead Sectors In Thursday Trading As Growth Trails
Five sectors are higher and six are lower in Thursday’s regular session, with defensive sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap…
-
1 week ago benzinga.com
Johnson & Johnson Announces Data From Its VARIPURE, Omny-IRE Trials Demonstrated 100% Of Participants Had Acute Procedural Success; Mean Ablation Rate Of 17.9 Minutes Observed
Johnson & Johnson (NYSE: JNJ) today announced new data from the late-breaking VARIPURE and Omny-IRE studies presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 Annual Meeting in Busan,…
1 week ago benzinga.com
Cyclicals Top Sectors In Wednesday Trading As Defensives Trail
Five sectors are higher and six are lower in Wednesday’s regular session, with cyclical sectors holding two of the top three positions alongside Technology. The leaders are separated rather than…
-
2 weeks ago benzinga.com
Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease
TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose groupThese findings…
-
2 weeks ago benzinga.com
Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287
Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $275 to $287.
2 weeks ago benzinga.com
9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead
Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing…
-
2 weeks ago benzinga.com
Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma
https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma
-
2 weeks ago benzinga.com
Morgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to $292
Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and lowers the price target from $294 to $292.